Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis.

As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will get an undisclosed upfront payment apart from an additional $291 million in the form of potential milestone payments based on certain development and commercial milestones, and also as royalties on yearly net sales.

John McHutchison – Gilead Sciences Chief Scientific Officer and Head of Research and Development, said: “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options.

The antiviral portfolio of Gilead Sciences includes drugs for the treatment of HIV, hepatitis B, and hepatitis C, and also influenza infection.

Related posts

• Aptar wins FDA approval for Unidose Powder System for nasal spray of hypoglycemia drug (0)
• Proteostasis begins dosing in phase 2 cystic fibrosis trial (0)
• Lilly secures Baqsimi FDA approval for severe hypoglycemia (0)
• Ligand acquires antigen-discovery company Ab Initio Biotherapeutics (0)
• La Jolla secures FDA orphan status for malaria candidate LJPC-0118 (0)
• AbbVie to acquire Botox developer Allergan for $63bn (0)
• Celgene bags Otezla FDA approval for oral ulcers in Behcet’s Disease (0)
• Rising to launch generic version of Pregabalin Capsules in US (0)
• PureTech Health acquires LYT-100 for lymphedema treatment (0)
• Merck bags Recarbrio FDA approval for urinary tract and intra-abdominal infections (0)

The post Gilead Sciences licenses three preclinical antiviral programs from Novartis appeared first on PharmaNewsDaily.com.